Standard BioTools to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Standard BioTools (NASDAQ: LAB) announced that its President and CEO, Michael Egholm, PhD, will present at the 43rd Annual J.P. Morgan Healthcare Conference. The event will be held from January 13th to 16th at the Westin St. Francis Hotel in San Francisco, CA. Dr. Egholm’s presentation is scheduled for January 16th, 2024, at 9:45 a.m. PT. A live audio webcast of the presentation will be accessible via the Investor Relations page on the company’s website. An archived recording will also be available for later access on the same page.

News Market Reaction – LAB

%

1 alert

% News Effect

On the day this news was published, LAB declined NaN%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

SOUTH SAN FRANCISCO, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced its President and Chief Executive Officer, Michael Egholm, PhD, will present at the upcoming 43^rd Annual J.P. Morgan Healthcare Conference taking place on January 13^th - 16^th at the Westin St. Francis Hotel in San Francisco, CA.

Dr. Egholm’s corporate presentation will be held on January 16^th, 2024, at 9:45 a.m. PT.

A live audio webcast will be available to investors and other interested parties by accessing the Investor Relations page of the Company’s website at Events & Presentations. A recording will be archived and available on the Standard BioTools Investor Relations page at investors.standardbio.com.

About Standard BioTools Inc.

Standard BioTools Inc. (Nasdaq: LAB), the parent company of SomaLogic Inc. and previously known as Fluidigm Corporation, has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop medicines faster and better. As a leading solutions provider, the company provides reliable and repeatable insights in health and disease using its proprietary SomaScan, mass cytometry and microfluidics technologies, which help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology and immunotherapy. Learn more at standardbio.com or connect with us on X, Facebook^®, LinkedIn, and YouTube™.

For Research Use Only. Not for use in diagnostic procedures.

Limited Use Label License and other terms may apply: standardbio.com/legal/salesterms.
Patent and License Information: standardbio.com/legal/notices.
Trademarks: standardbio.com/legal/trademarks. Any other trademarks are the sole property of their respective owners. ©2024 Standard BioTools Inc. (f.k.a. Fluidigm Corporation). All rights reserved.

Investor Contact

David Holmes
Gilmartin Group LLC
ir@standardbio.com

FAQ

When will Standard BioTools present at the J.P. Morgan Healthcare Conference?

Standard BioTools will present on January 16th, 2024, at 9:45 a.m. PT.

Who is presenting for Standard BioTools at the J.P. Morgan Healthcare Conference?

Michael Egholm, PhD, President and CEO of Standard BioTools, will be presenting.

Where is the 43rd Annual J.P. Morgan Healthcare Conference being held?

The conference will be held at the Westin St. Francis Hotel in San Francisco, CA.

How can I access the live webcast of Standard BioTools' presentation?

The live webcast will be available on the Investor Relations page of Standard BioTools' website.

Will there be an archived recording of the Standard BioTools presentation?

Yes, an archived recording will be available on the Standard BioTools Investor Relations page.